Spyglass Pharma (NASDAQ:SGP) Shares Down 4.5% - What's Next?

Key Points

• Spyglass Pharma shares fell 4.5% to about $24.81, with trading volume 83% below the stock’s average session volume.
• Analyst sentiment remains generally positive, with six Buy ratings, one Hold, and one Sell; the stock has a Moderate Buy consensus and an average price target of $44.00.
• The clinical-stage ophthalmic company missed quarterly earnings expectations, reporting a loss of $0.59 per share versus the $0.48 consensus estimate, while institutional investors—including Affinity Asset Advisors—built new positions.

Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report)'s share price fell 4.5% during trading on Tuesday. The company traded as low as $24.93 and last traded at $24.8110. 19,056 shares were traded during mid-day trading, a decline of 83% from the average session volume of 109,914 shares. The stock had previously closed at $25.98.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Raymond James Financial initiated coverage on Spyglass Pharma in a research report on Friday, August 14th. They set an "outperform" rating and a $39.00 target price on the stock. Weiss Ratings cut shares of Spyglass Pharma from a "sell (e+)" rating to a "sell (e)" rating in a research report on Friday. Finally, Wall Street Zen raised shares of Spyglass Pharma from a "sell" rating to a "hold" rating in a report on Saturday, September 19th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Spyglass Pharma presently has an average rating of "Moderate Buy" and an average target price of $44.00.

Spyglass Pharma Trading Down 4.4%

The company has a market cap of $829.87 million and a price-to-earnings ratio of -3.55. The stock's fifty day simple moving average is $25.86 and its 200 day simple moving average is $23.36.

Spyglass Pharma (NASDAQ:SGP - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.11). On average, analysts predict that Spyglass Pharma, Inc. will post -2.55 EPS for the current year.

Institutional Investors Weigh In On Spyglass Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SGP. The Manufacturers Life Insurance Company purchased a new stake in Spyglass Pharma in the 1st quarter valued at about $308,000. Bank of New York Mellon Corp acquired a new position in shares of Spyglass Pharma in the second quarter worth $533,000. Bank of America Corp DE purchased a new stake in Spyglass Pharma during the 1st quarter worth about $726,000. Monashee Investment Management LLC purchased a new stake in shares of Spyglass Pharma during the first quarter worth approximately $2,461,000. Finally, Affinity Asset Advisors LLC purchased a new stake in shares of Spyglass Pharma in the 1st quarter valued at approximately $6,478,000.

Spyglass Pharma Company Profile

SpyGlass Pharma, Inc is a clinical-stage ophthalmic pharmaceutical company focused on developing long-acting treatments for chronic eye diseases. The company is developing drug-delivery technologies intended to reduce the need for patients to administer topical eye drops regularly.

Its lead development program, SGP-310, is an intraocular implant designed to provide sustained delivery of travoprost, a prostaglandin analog used to lower elevated intraocular pressure. The product is being developed for patients with primary open-angle glaucoma or ocular hypertension, conditions that can increase the risk of vision loss if left untreated.

SpyGlass Pharma's platform is intended to support extended drug release inside the eye, potentially improving treatment consistency and adherence compared with daily topical medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.